Elisabet de los Pinos, Aura Biosciences CEO
October 29, 2021 08:46 AM EDTUpdated 10:20 AM
Financing

In­tra­cel­lu­lar tar­gets, eye can­cer ther­a­py and light-ac­ti­vat­ed skin­care: Here's the lat­est on biotech IPOs

Nicole DeFeudis

Editor

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

The busy IPO sea­son shows no sign of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

FDA lifts hold on En­trada's Duchenne drug af­ter two years

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times